diethyl 2-(((3-iodophenyl)amino)methylene)malonate | 22200-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl 2-(((3-iodophenyl)amino)methylene)malonate
• 英文别名: (3-iodo-anilinomethylene)-malonic acid diethyl ester；[N-(3-Jod-phenyl)-formimidoyl]-malonsaeure-diaethylester；(3-Jod-anilinomethylen)-malonsaeure-diaethylester；diethyl 2-((3-iodophenylamino)methylene)malonate；diethyl{[(3-iodophenyl)amino]methylene}malonate；diethyl 2-[(3-iodoanilino)methylidene]propanedioate
• CAS: 22200-47-1
• 化学式: C₁₄H₁₆INO₄
• 分子量: 389.19
• InChiKey: TUQHTOJOJGWLLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  diethyl 2-(((3-iodophenyl)amino)methylene)malonate 在 sodium hydroxide 、 三氯氧磷 作用下， 以 二苯醚 为溶剂， 反应 2.17h， 生成 4-氯-7-碘喹啉
  参考文献：
  名称：

  Structure−Activity Relationships for Antiplasmodial Activity among 7-Substituted 4-Aminoquinolines

  摘要：

  Aminoquinolines (AQs) with diaminoalkane side chains (-HNRNEt2) shorter or longer than the isopentyl side chain [-HNCHMe(CH2)(3)NEt2] of chloroquine are active against both chloroquine-susceptible and -resistant Plasmodium falciparum. (De, D.; et al. Am. J. Trop. Med. Hyg. 1996, 55, 579-583). In the studies reported here, we examined structure-activity relationships (SARs) among AQs with different N,N-diethyldiaminoalkane side chains and different substituents at the 7-position occupied by Cl in chloroquine. 7-Iodo- and 7-bromo-AQs with diaminoalkane side chains [-HN(CH2)(2)NEt2, -HN(CH2)(3)NEt2, or -HNCHMeCH2NEt2] were as active as the corresponding 7-chloro-AQs against both chloroquine-susceptible and -resistant P. falciparum (IC(50)s of 3-12 nM). In contrast, with one exception, 7-fluoro-AQs and 7-trifluoromethyl-AQs were less active against chloroquine-susceptible P. falciparum (IC(50)s of 15-50 nM) and substantially less active against chloroquine-resistant P. falciparum (IC(50)s of 18-500 nM). Furthermore, most 7-OMe-AQs were inactive against both chloroquine-susceptible (IC(50)s of 17-150 nM) and -resistant P. falciparum (IC(50)s of 90-3000 nM).

  DOI：

  10.1021/jm980146x
• 作为产物：
  描述：

  乙氧基甲叉丙二酸二乙酯 、 3-碘苯胺 以97%的产率得到diethyl 2-(((3-iodophenyl)amino)methylene)malonate
  参考文献：
  名称：

  4-氯-7-碘喹啉-3-羧酸乙酯的合成，结构与构象分析及红外光谱

  摘要：

  在这项工作中，我们报告了一种新型喹啉衍生物4-氯-7-碘喹啉-3-羧酸乙酯（CIQC）的合成及其结构，构象和振动表征。研究了该化合物的纯净固相（结晶和低温非晶相），以及作为低温氩气基质中的分离物（约15 K）。红外光谱法和单晶X射线衍射是选择的实验技术。理论上也以近似的B3LYP / LANL2DZ + cc-pVDZ水平研究了化合物分离分子的构象空间和振动光谱。 CIQC分子以四个不同的构象异构体存在，室温（rt）的预测种群为42：25：17：16％。将rt平衡构象混合物成功捕获在15 K的氩气基质中，并确​​定构象异构体的振动特征。在较高温度（约40 K）下对化合物的基质进行退火后，发现高能形式转化为最稳定的构象异构体，同时构象异构化的预测障碍较低。基质氩原子的升华（约43 K）导致产生了CIQC的低温非晶态，它含有最低但也较高的能量构象异构体。在T 〜233–243 K，非晶态重排至

  DOI：

  10.1016/j.tet.2015.07.076

文献信息

• Compounds and Methods of Treatment
  申请人：LACKEY Karen Elizabeth

  公开号：US20080234267A1

  公开（公告）日：2008-09-25

  A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.

  本文描述了一种作为Ret酪氨酸激酶抑制剂有用的衍生物。所述发明还包括使用相同物质治疗由不当的Ret酪氨酸激酶活性介导的疾病的方法。
• [EN] NOVEL QUINOLINE DERIVATIVES<br/>[FR] DERIVES NOUVEAUX DE QUINOLEINE
  申请人：PFIZER

  公开号：WO2005063739A1

  公开（公告）日：2005-07-14

  The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  该发明涉及由式(I)表示的化合物，以及所述化合物的药学上可接受的盐或溶剂化合物，其中A、R3-8、X3、X5、m和n在此处被定义。该发明还涉及含有式(I)化合物的药物组合物，以及通过给予式(I)化合物治疗哺乳动物的增生性疾病的方法。
• [EN] HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES D'URÉE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2009147433A1

  公开（公告）日：2009-12-10

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化学式（I）的化合物及其药用盐。还描述了它们的制备过程、含有它们的药物组成、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• NOVEL QUINOLINE DERIVATIVES
  申请人：Hong Yufeng

  公开号：US20090069316A1

  公开（公告）日：2009-03-12

  The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R 3-8 , X 3 , X 5 , m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

  该发明涉及由公式（I）表示的化合物，以及该化合物的药学上可接受的盐或溶剂，其中在此定义了A、R3-8、X3、X5、m和n中的每个。该发明还涉及包含公式（I）化合物的药物组合物，以及通过给予公式（I）化合物来治疗哺乳动物的过度增殖性疾病的方法。
• HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Choy Allison Laura

  公开号：US20100190745A1

  公开（公告）日：2010-07-29

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了式(I)的化合物及其药学上可接受的盐。还描述了它们的制备过程、含有它们的制药组合物、它们作为药物的使用以及它们在治疗细菌感染方面的使用。